Rahila Angelova Mbal AD
- Address
- Ulitsa Breznik 2, 2300 Pernik, Bulgaria
Rahila Angelova MBAL AD - Multidisciplinary Clinical Research Center
Rahila Angelova MBAL AD is a comprehensive clinical research facility specializing in diverse therapeutic areas, with particular expertise in respiratory diseases, renal disorders, and infectious diseases. The center demonstrates substantial capabilities in conducting complex phase 2 and 3 clinical trials across multiple medical disciplines, serving both adult and adolescent patient populations.
- Chronic Respiratory Diseases: COPD, severe asthma, and bronchiectasis treatment optimization studies
- Chronic Kidney Disease (CKD) and Hypertension: cardiovascular-renal outcome trials
- Infectious Disease Management: COVID-19 therapeutics for high-risk patients
- Advanced Drug Delivery Systems: novel propellant formulations and biologic therapies
The research center has established significant expertise in evaluating innovative therapeutic approaches, including combination therapy trials for chronic kidney disease with concurrent hypertension, biologic agents for severe asthma, and advanced inhaled medication delivery systems for chronic obstructive pulmonary disease. With experience in pulmonary exacerbation prevention and antiviral therapeutics, Rahila Angelova MBAL AD demonstrates versatility in addressing both chronic disease management and acute infectious disease challenges, positioning itself as a valuable partner for pharmaceutical companies developing next-generation treatments across multiple therapeutic domains.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1AstraZeneca AB3active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Rahila Angelova Mbal AD
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Assessment of Lung Function Equivalence of Budesonide, Glycopyrronium Bromide, and Formoterol Fumarate MDI HFO vs. MDI HFA in COPD Patients Aged 40-80 | AstraZeneca AB | Phase III | Not Recruiting | Jun 2024 | Jul 2025 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Baxdrostat | 2 | Unknown | 2025-05-07 | 2026-04-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.